Gardens By The Bay Bridge
Pregnancy and lactation
Piroxicam is contraindicated for use in the III trimester of pregnancy.
If necessary, use in the I and II trimesters of pregnancy should correlate the expected benefits to the mother and the potential risk to the fetus, due to the lack of reliable clinical data confirming the safety of piroxicam during this period. NSAIDs may cause premature closure of the botallal duct in the fetus.
Piroxicam is excreted in breast milk. piroxicam online If necessary, use during lactation should decide on the termination of breastfeeding.
Indications for use:
For systemic and external use: articular syndrome (rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout), pain in the spine, neuralgia, myalgia, traumatic inflammation of the soft tissues and musculoskeletal system. For systemic use: dysmenorrhea in patients over 12 years old, acute infectious and inflammatory diseases of the upper respiratory tract.
Interaction of piroxicam with other substances
Piroxicam displaces other drugs from communication with blood proteins. Piroxicam reduces the effectiveness of antihypertensive drugs. While taking corticosteroids and other non-steroidal anti-inflammatory drugs, the risk of ulcerogenic exposure to piroxicam increases. The risk of developing hyperkalemia increases with the combined use of piroxicam with potassium-containing drugs and potassium-sparing diuretics. Piroxicam increases the concentration of lithium and phenytoin in the blood. With the combined use of piroxicam and anticoagulants, the risk of bleeding increases. Acetylsalicylic acid reduces the content of piroxicam in the blood by 20%.
Pharmacological properties
Piroxicam inhibits the activity of the enzyme cyclooxygenase 1 and 2, reduces the production of thromboxanes and prostaglandins (including PGE1, PGE2 alpha, PGE2). http://www.drugs.com/pro/piroxicam.html Piroxicam inhibits platelet aggregation and phagocytosis. When ingested, piroxicam is well absorbed from the gastrointestinal tract, the maximum concentration is reached after 3-5 hours. Within 7-12 days, the equilibrium concentration of piroxicam in the blood is established. With plasma proteins, the drug binds to 97–99%. In the liver, piroxicam undergoes metabolism (conjugates and oxidizes) to form the main metabolites of N-methyl-benzosulfonamide, 5-hydroxypyroxicam and others, which are pharmacologically inactive.
The half-life of piroxicam is approximately 50 hours, with liver diseases it can increase. It is excreted by piroxicam by the kidneys and intestines (in the urine the amount of the drug is 2 times greater than in feces), mainly in the form of glucuronides (5% is excreted unchanged). Piroxicam is excreted in breast milk and passes through the placenta. In the body does not cumulate.
Pyroxicam weakens pain, inflammation symptoms with any method of use. With joint syndrome, pain and inflammation in the joints stops or weakens when moving and at rest, reduces swelling and morning stiffness of the joints. In studies of chronic and subacute toxicity in animals, it was shown that the most frequent manifestation of toxicity with prolonged use of piroxicam is damage to the gastrointestinal tract and renal papillary necrosis. No teratogenic effects and effects on fertility in animals were found. Piroxicam increases the possibility of delaying the birth act and pathological birth in animals. The toxic effect of piroxicam on the gastrointestinal tract is especially pronounced in women in the third trimester of pregnancy.